Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 1,635 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total value of $36,624.00. Following the completion of the transaction, the chief financial officer owned 85,034 shares of the company's stock, valued at $1,904,761.60. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Howard Horn also recently made the following trade(s):
- On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.70, for a total value of $190,884.30.
- On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16.
- On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78.
Ultragenyx Pharmaceutical Stock Performance
Ultragenyx Pharmaceutical stock opened at $22.07 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $42.37. The firm has a 50 day moving average price of $23.82 and a 200 day moving average price of $29.24. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -3.78 and a beta of 0.16.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same quarter last year, the business earned ($1.39) EPS. The firm's revenue for the quarter was up 25.5% compared to the same quarter last year. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the stock. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a "buy" rating for the company in a research report on Monday, January 5th. Wedbush reaffirmed a "neutral" rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. Robert W. Baird cut their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 30th. Bank of America dropped their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a "buy" rating on the stock in a report on Friday, January 2nd. Finally, Jefferies Financial Group lowered their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a "buy" rating for the company in a research report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $68.29.
Read Our Latest Research Report on RARE
Trending Headlines about Ultragenyx Pharmaceutical
Here are the key news stories impacting Ultragenyx Pharmaceutical this week:
- Positive Sentiment: Institutional buying: several large funds have recently increased or initiated stakes (notably Norges Bank and Frazier Life Sciences), which supports a base of long‑term institutional demand and can help stabilize the float. Institutional Inflows
- Neutral Sentiment: Management presentation transcript from TD Cowen’s healthcare conference is available—useful for updating pipeline timelines and modeling but contains no new regulatory or commercial outcomes. TD Cowen Presentation Transcript
- Negative Sentiment: Heavy insider selling by multiple senior executives, including CEO Emil Kakkis (54,404 shares) and several EVPs/C‑suite officers selling material blocks at ~ $22.7–22.8—markets often view clustered executive sales as a negative near‑term sentiment signal. SEC filing for the CEO sale: Insider Sale SEC Filing
- Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and one class action has been filed alleging misstatements/omissions tied to setrusumab (class period Aug 3, 2023–Dec 26, 2025). Proliferating notices and a filed suit raise potential legal and financial exposure and are likely pressuring the stock. Example filing/notice: Class Action Notice
Institutional Trading of Ultragenyx Pharmaceutical
Several institutional investors have recently added to or reduced their stakes in RARE. Assetmark Inc. grew its holdings in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank increased its holdings in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 393 shares during the last quarter. Danske Bank A S bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at about $39,000. Smartleaf Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 1,169 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 369 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Company Profile
(
Get Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
